• Explore /
  • Poster
  • / Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.

Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.

Abstract Poster

Authors

null

Francesca Corti

Medical Oncology Department, ENETS Center of Excellence, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Francesca Corti , Vito Amoroso , Davide Campana , Maria Pia Brizzi , Francesco Panzuto , Ivana Puliafito , Natalie Prinzi , Massimo Milione , Monica Niger , Maria Antista , Alessandra Raimondi , Federica Morano , Michele Prisciandaro , Teresa Beninato , Filippo Pagani , Giovanni Randon , Iolanda Pulice , Maria Di Bartolomeo , Filippo G. De Braud , Sara Pusceddu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

NCT04427787

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS4167)

DOI

10.1200/JCO.2021.39.15_suppl.TPS4167

Abstract #

TPS4167

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Katy Beckermann

First Author: Michelle Wilson

First Author: Michael J. Demeure

First Author: Ryan Huu-Tuan Nguyen